Investor Relations

Our Mission

Senti Bio was founded with the intention to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches.

Founded on Smart Science

Senti Bio is a clinical-stage company with a proprietary synthetic biology platform for programming next-generation cell and gene therapies with Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. We are applying our Gene Circuit technologies to develop a pipeline of product candidates that use off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells.

Driven by Strong Leadership

Senti Bio is led by seasoned professionals with a passion for advancing life-changing therapies.

Co-Founder and Chief Executive Officer, Dr. Tim Lu, is a pioneer in synthetic biology and has co-founded multiple therapeutics platform companies including Synlogic, Tango Therapeutics, Eligo Bioscience, BiomX and Engine Biosciences. Chief Financial Officer, Jay Cross, is a proven financial leader with extensive experience as a healthcare investment banker on Wall Street. President, Head of Research & Development and Chief Medical Officer, Dr. Kanya Rajangam, is an experienced biotechnology executive with an extensive track record of successfully obtaining commercial approval for multipe products globally across multiple modalities including allogeneic cell therapies.